The skinny on fatty acid-binding protein.

iomarkers have come to play an increasingly important ole in the evaluation and management of patients with uspected acute coronary syndromes (ACS). To date, cariac troponins T and I remain the best established biomarers in ACS for both diagnosis and risk assessment. In ddition to providing high sensitivity and specificity for etecting myocardial necrosis, troponins provide assessment f the risk of adverse outcomes in patients with ACS and elp to identify patients who benefit most from particular reatment strategies, including glycoprotein IIb/IIIa inhibtors, low molecular-weight heparins, and routine coronary ngiography (1).